An ensemble learning system for a 4-way classification of Alzheimer's disease and mild cognitive impairment

Dongren Yao1, Vince D Calhoun2, Zening Fu3

  • 1Brainnetome Center and NLPR, Institute of Automation, CAS, Beijing, China; University of Chinese Academy of Sciences, Beijing, China.

Insights

This study developed a machine learning method to classify Alzheimer's disease (AD) and mild cognitive impairment (MCI) subtypes using brain MRI scans. The approach achieved 54.38% accuracy, identifying key brain features for early diagnosis.

Area of Science:

  • Neuroimaging
  • Machine Learning
  • Neurology

Background:

  • Distinguishing Alzheimer's disease (AD) from mild cognitive impairment (MCI) is crucial for early intervention.
  • Classifying MCI subtypes (those converting to AD vs. not) presents a significant clinical challenge.

Purpose of the Study:

  • To develop a machine learning framework for a 4-way classification: AD, MCI, MCI converters (cMCI), and healthy controls.
  • To improve classification accuracy by employing a hierarchical approach and novel feature selection.

Main Methods:

  • A hierarchical classification strategy was implemented, breaking the 4-way problem into five binary classifications.
  • A feature selection method based on relative importance was developed to identify a concise subset of MRI and demographic features.
  • The approach utilized T1-weighted MRI data and demographic information from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database.

Main Results:

  • The proposed method achieved a 54.38% accuracy in the 4-way classification on testing data.
  • Approximately 2% of the original features were selected, creating a more informative feature space.
  • Selected features, including hippocampal volume and parahippocampal surface area, align with known AD/MCI-related brain changes.

Conclusions:

  • The hierarchical classification and feature selection framework offers a promising approach for multi-class neurodegenerative disease classification.
  • The method demonstrates potential for enhancing early diagnosis and understanding of AD progression.
  • The identified discriminative features provide insights into the neurobiological underpinnings of AD and MCI.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...